Direct Meds Review: One Flat Price, and an FDA Letter

Direct Meds is unusual on our board for a small reason that turns out to be the most interesting thing about it: the price does not move. Sermorelin is $199 a month whether you select the 30-day supply or the 90-day supply. Almost every other provider we track uses the longer term to advertise a lower headline; this one does not. It is also the subject of an FDA warning letter issued in September 2025, and both facts belong on the same page.

The FDA warning letter

The FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We are stating it plainly because the company appears on our sermorelin boards and in our GLP-1 section, and we earn a commission when a reader starts care through some of the links on this site. Someone about to hand this company a card number should know the letter exists first.

We are deliberately not paraphrasing the agency's allegations. A warning letter is a formal public document, and the version that matters is the FDA's own wording rather than a summary written by a site with a commercial interest in the company. It is searchable by company name in the FDA's warning-letter database¹ — read it there.

How we are treating it, consistently with the other two companies on this site in the same position: DirectMeds stays listed and its links stay live. A warning letter is a compliance action, not a ruling that a company cannot operate, and deleting a provider from a comparison page does not help the reader already looking at that page — it just makes our page less complete than the market it claims to describe. What changes is that every surface here that ranks or profiles the company now carries the letter and its date.

The flat price, and what it is not

Sermorelin is $199 a month, injectable, marketed by the company as "about $6.42 per day". Toggle between the 30-day and 90-day supply and the monthly figure is identical. There is no membership and no separate consult fee.

Read that honestly in both directions. It is genuinely straightforward: there is no commitment arithmetic to do, no prepay tier dangling a lower number, and none of the prepay-as-monthly confusion that makes some competitors' headlines so misleading. But a flat price is not automatically a good price — $199 sits at the top of the month-to-month range on our board, and buying three months at once earns you nothing at all, which is the opposite of how the rest of the category behaves. If you were going to commit to a quarter anyway, you are paying a premium for the privilege elsewhere and merely not being rewarded here. Our price-sorted board shows where $199 actually lands, and what sermorelin costs per month explains the spread.

Two things the product page does not publish: the mcg strength behind the $199, and which states it serves. Strength matters more than it sounds — a monthly price is only comparable against another monthly price at a comparable dose, and without the strength the figure is not fully checkable.

What it sells, and how the claims read

DirectMeds is a broad telehealth catalogue — weight loss, anti-aging, skin, energy, hormone health, sexual health, pain relief, hair. Sermorelin is sold under the product name Sermorix as its own line item rather than an add-on, which is better than the tier-floor pricing several competitors use.

Its sermorelin copy leads on the outcome this site cares about: "One of the first benefits users notice is deeper, more restful sleep." That ordering is defensible — sleep is the best-supported of sermorelin's marketed effects, since GHRH given to healthy men measurably increases slow-wave sleep alongside the expected growth-hormone release².

Two claims on the same page are weaker than the language suggests. "Clinically Proven Peptide Therapy" overstates what exists: sermorelin reliably moves GH and IGF-1 short-term, but there is no modern outcome trial demonstrating the body-composition or anti-aging benefits it is sold for³. And describing it as "a safer and more sustainable option" than synthetic HGH is a comparative safety claim without a comparative safety trial behind it. The mechanism argument for preferring a secretagogue is reasonable; calling the result proven and safer is not. Our pillar evidence guide sets out what the record actually supports, and sermorelin side effects covers the rest.

The GLP-1 side, and a number that does not add up

The same company appears in our GLP-1 section, because weight loss is the intervention with the strongest effect on obstructive sleep apnea — see GLP-1 for sleep apnea. Its published figures are injectable semaglutide $297/month, injectable tirzepatide $399/month, and sublingual semaglutide from $249/month. All compounded, so none is FDA-approved and none is the same product as Wegovy or Zepbound.

One checkable slip worth flagging, because it is the sort of thing that erodes confidence in every other figure on a site: the tirzepatide page prints "$9.58 per day" beside its $399 monthly price. $9.58 a day is the semaglutide figure ($297 across 31 days). At $399 the real per-day cost is closer to $13. It is a copy-paste error rather than anything sinister, but it is on the page where the customer decides, and it understates the daily cost of the more expensive drug by about a third.

Bottom line

DirectMeds prices sermorelin simply and publishes it up front, sells it as a real product rather than a tier floor, and leads its marketing with the benefit the evidence best supports. Against that: $199 is at the expensive end and the 90-day supply saves nothing, the strength and served states are unpublished, two of its efficacy claims are stronger than the evidence, its tirzepatide per-day figure is wrong on the page, and the FDA issued the company a warning letter in September 2025. Read the letter in the FDA's own database, and if you are comparing providers on price, compare at a stated dose — our where to buy sermorelin online page lays the options out.